title: [Effects of aprotinin on blood loss reduction in children undergoing repair of tetralogy of Fallot].
abstract: The effect of aprotinin on the blood loss reduction was studied in children undergoing repair of tetralogy of Fallot. We administered aprotinin to consecutive 21 patients during the repair of tetralogy of Fallot and examined the blood loss and operative time in comparison with that in a control group of 20 patients. 30,000 KIU/kg of aprotinin was infused as the initial cardiopulmonary bypass (CPB) dose and 10,000 KIU/kg/hr was continuously administered as the maintenance dose during CPB. There was no resternotomy case due to bleeding and no operative death in both groups. Blood loss after CPB during operation and total blood loss during operation were significantly lower in aprotinin group than in control group. There were no differences between two groups in the volume of chest tube drainage in the postoperative 24 hours and the duration of chest tube drainage. Time from cessation of CPB to skin closure and total operative time were significantly shorter in aprotinin group than in control group. In conclusion, aprotinin was effective on the reduction of blood loss and the shortening of operative time in children undergoing repair of tetralogy of Fallot.
authors.affiliation: Department of Surgery, Hyogo Prefectural Kaibara Hospital, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Imai
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: H
authors.initials: H
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Oshima
authors.forename: M
authors.initials: M
authors.lastname: Aoyama
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D007611:Aprotinin / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass; D002648:Child; D002675:Child, Preschool; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D013771:Tetralogy of Fallot / Q000601:surgery*
chemical_list: D006490:Hemostatics; D007611:Aprotinin